Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | IL1B | P01584 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918105 | 0.84 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL25323352 | 0.84 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL25323350 | 0.84 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL8007592 | 0.80 | NR1H2 (0.40) | NR1H2RECQLHSD17B10CHRM2CHRM1 | |
| SCHEMBL17686396 | 0.80 | — | — | |
| SCHEMBL9918104 | 0.79 | NR1H2 (0.42) | NR1H2RECQLHSD17B10CHRM2CHRM1 | |
| SCHEMBL29202406 | 0.79 | NR1H2 (0.39) | NR1H2RECQLHSD17B10CHRM2CHRM1 | |
| SCHEMBL2079719 | 0.79 | CCR2 (0.37) | NR1H2RECQLCHRM2CHRM1CHRM3 | |
| SCHEMBL29081315 | 0.78 | NR1H2 (0.38) | NR1H2RECQLHSD17B10HPGDCHRM2 | |
| SCHEMBL29081317 | 0.78 | NR1H2 (0.38) | NR1H2RECQLHSD17B10HPGDCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | TBXA2R, XDH, CYP4X1 | NR1H2 1432/4885RECQL 1755/4885HSD17B10 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.